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Objectives The study was to explore whether the brachial/carotid pulse pressure (B/C-PP) ratio selectively predicts the sex
difference in age-related cardiovascular (CV) death.
Background Hypertension and CV complications are more severe in men and post-menopausal women than in pre-
menopausal women. C-PP is lower than B-PP, and the B/C-PP ratio is a physiological marker of PP amplification
between B and C arteries that tends toward 1.0 with age.
Methods The study involved 72,437 men (ages 41.0  11.1 years) and 52,714 women (39.5  11.6 years). C-PP was
calculated for each sex by a multiple regression analysis including B-PP, age, height and risk factors, and a
method validated beforehand in a subgroup of 834 subjects. During the 12 years of follow-up, 3,028 men and
969 women died.
Results In the total population, the adjusted hazard ratios (HR) (95% confidence interval [CI]) of B/C-PP ratio were:
1) for all-cause mortality: men, HR: 1.51 (95% CI: 1.47 to 1.56), women; HR: 2.46 (95% CI: 2.27 to 2.67) (p 
0.0001); and 2) for CV mortality: men, HR 1.81 (95% CI: 1.70 to 1.93); women, HR: 4.46 (95% CI: 3.66 to 5.45)
(p  0.0001). The B/C-PP impact on mortality did not significantly increase from younger men to those 55
years of age, from: HR: 1.44 (95% CI: 1.31 to 1.58) to HR 1.65 (95% CI: 1.48 to 1.84), but increased signifi-
cantly with age in women: HR: 3.19 (95% CI: 2.08 to 4.89) versus HR: 5.60 (95% CI: 4.17 to 7.50) (p  0.01).
Thus, the mortality impact of B/C-PP ratio was 3-fold higher in women than in men 55 years old.
Conclusions PP amplification is highly predictive of differences in CV risk between men and women. In post-menopausal
women, the attenuation of PP amplification, mainly related to increased aortic stiffness, contributes to the
significant increase in CV risk. (J Am Coll Cardiol 2012;59:1771–7) © 2012 by the American College of
Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2012.01.044A greater incidence of hypertension and cardiovascular
(CV) complications is widely observed in men and post-
menopausal women compared with pre-menopausal
women. This epidemiological finding suggests that the
female sex hormone estrogen and, to a lesser extent, the sex
hormones progesterone and testosterone, possess, under
clinical situations, significant vascular protective properties
that disappear after menopause (1–7). However, recently,
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012, accepted January 6, 2012.the effects of menopausal hormonal therapy (MHT), as well
as data from randomized clinical trials such as the Women’s
Health Initiative study, challenged the hypothesis of the
potential CV benefits of estrogen treatment (6,7). In these
studies, the major role of blood pressure (BP) was poorly
taken into consideration: more than one-third of the pa-
tients were hypertensive (38%).
Studies of pulsatile arterial hemodynamics have shown
that BP in women presents very particular hemodynamic
characteristics. First, there are classically 2 distinct compo-
nents of BP: mean arterial pressure (MAP) and pulse
pressure (PP) (8). Although MAP refers exclusively to
steady pressure, vascular resistance and, hence, small arter-
ies, PP refers to pulsatile pressure that has 3 determinants:
stroke volume, arterial stiffness, and wave reflections. Only
the latter 2 factors impinge on PP in large arteries and, in
post-menopausal women, the role of PP predominates over
that of MAP in the mechanism of high BP. Second,
physiologically, PP and systolic BP (SBP) are consistently
higher in peripheral than in central arteries for the same
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(8,9). This aspect, called SBP or
PP amplification, is due to the
changes in arterial stiffness, princi-
pally affecting the propagation of
the pressure wave and wave reflec-
tions along the arterial tree (9). In
post-menopausal women (10–12),
SBP and PP amplification are
considerably attenuated because
central SBP and PP increase more
rapidly with age than do brachial
SBP or PP. Consequently, the
brachial to carotid PP ratio (B/C)
decreases with aging and arterial
stiffness.
Recently, our group showed
that brachial (B) PP, carotid (C)
PP, and the B-PP/C-PP ratio
(or B/C ratio) are all significant
and independent CV risk factors
and that the most powerful pre-
ictor of CV death is the B/C ratio (13). In the present
tudy, our aim was to compare the respective impacts of
-PP, B-PP, or B/C ratio on mortality rates. Our working
ypothesis is that the B/C ratio should be more significantly
ssociated with the sex difference in age-dependent CV risk
han C-PP or B-PP. To assess the observed mortality rates
n both sexes in the general low-to-moderate risk popula-
ion, we studied a large sample of 125,151 subjects. We
etermined mathematically the central carotid artery PP by
n equation established in an independent sample of 834
ubjects. Calculated for epidemiological purpose, this equa-
ion is not applicable to evaluation of C-PP in clinical
ractice.
ethods
ubjects. Subjects were examined at the IPC (“Investiga-
ions Preventives et Cliniques”) Center (Paris, France). This
edical center, which is subsidized by the French national
ealth care system (Sécurité Sociale-CNAMTS), offers a
ree medical examination to working and retired individuals
nd their families and, thus, carries out approximately
5,000 health examinations per year for inhabitants of the
aris area.
The IPC study population consisted of 72,437 men (age
1.0  11.1 years) and 52,714 women (age 39.5  11.6
years) who had a health checkup at the IPC Center between
January 1981 and December 1988 (Table 1). Subjects with
previous CV disease were excluded, to focus on primary
prevention. Although the specific date of menopause was
not available in our global database, in a more recent cohort
of 35,000 women examined in the IPC center, we found
that after the age of 55 years, 98% had gone through
Abbreviations
and Acronyms
B/C  brachial/carotid
BP  blood pressure
B-PP  brachial pulse
pressure
CI  confidence interval
C-PP  carotid pulse
pressure
CV  cardiovascular
DBP  diastolic blood
pressure
HR  hazard ratio
MAP  mean arterial
pressure
MHT  menopausal
hormonal therapy
PP  pulse pressure
SBP  systolic blood
pressuremenopause (data not shown). As a consequence, in thepresent study, women 55 years of age were considered as
being post-menopausal.
Antihypertensive drug therapy (present or past) involved
4,499 patients (3.60% of the IPC population). The
follow-up ended in 1998. During this period (mean dura-
tion: 12.1  2.2 years), 3,028 men and 969 women died.
Among these deaths, CV disease was responsible in 600
men and 135 women. The measurement methods employed
were described in detail elsewhere (14). Briefly, supine BP
was measured in the right arm using a manual mercury
sphygmomanometer, after a 10-min rest period. The first
and the fifth Korotkoff sounds were used to define SBP and
DBP. The mean of 3 measurements was considered as the
peripheral BP value. B-PP was calculated as SBP  DBP.
Heart rate was classified in the database, according to
categories with arbitrary cutoff points: 60, 60 to 80, 80 to
100, and 100 beats/min. Height (using a wall-mounted
stadiometer) and weight (using calibrated scales) were
recorded by a nurse. Standard biological parameters, includ-
ing total plasma cholesterol, triglycerides, and glycemia,
were measured under fasting conditions, and a resting
electrocardiogram was recorded. Heart rate was measured
on the electrocardiogram. Tobacco consumption (present:
yes/no), physical activity (exercising 1 h of walking per
day: yes/no), and personal medical history were assessed
using a self-administered questionnaire. All clinical and
biological parameters were evaluated on the same day of the
examination.
Brachial and central carotid blood pressure measurements.
To assess the mortality rates associated with CV causes in
such a low-to-moderate CV risk population, we needed a
large sample of subjects. As direct measurements of central
carotid artery PP are not available in such a large popula-
tion, at least in our institution, and at the time of recruit-
ment, we determined this parameter mathematically from
B-PP, using an equation first evaluated in an independent
sample of 834 subjects and then validated in a second
independent population of 285 individuals.
To assess a method of calculating C-PP, we selected a
population of 834 subjects, taken from the Hotel Dieu
Hospital population (MES), who had C-PP measured by
applanation tonometry. The aim was to develop a method to
determine C-PP by calculation, using multiple regression
analysis associating B-PP (measured by sphygmomanome-
try), some significant risk factors, and other hemodynamic
and biochemical variables (11,12,15,16), and to validate the
method by comparison with C-PP values measured directly
by tonometry. A complete description of the procedure is
given in Benetos et al. (13).
Briefly, in 834 subjects, brachial BP determinations were
performed in the supine position after a 15-min rest in the
laboratory by traditional mercury sphygmomanometry.
Central BP determinations were made by performing radial
and carotid artery applanation tonometry using a high-
fidelity Millar strain gauge transducer (SPT-301, Millar
Instruments, Houston, Texas) (8,11,12,17–19). The derived
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May 15, 2012:1771–7 Sex Difference and PP Amplificationpressure waveforms were recorded on a Gould 8188 re-
corder (Gould Electronic, Boulainvilliers, France) at a paper
speed of 100 mm/s. Radial artery pressure waveform,
calibrated from brachial artery SBP and DBP, was used for
the determination of peripheral MAP via application of an
integration method. Because DBP and MAP differences
throughout the arterial tree do not exceed 2 to 3 mm Hg
(8,17,20,21), the resulting carotid BP wave was calibrated
using brachial DBP and MAP. MAP, computed from the
area method, was assumed to be equal to peripheral mean
BP to calculate the amplitude of the carotid pressure
waveform as well as C-PP and SBP. C-PP is considered a
close surrogate of aortic PP (22,23).
The reproducibility of hemodynamic measurements has
been published in detail elsewhere, particularly regarding
C-PP (22,23). PP amplification between C-PP and B-PP
(mm Hg) was calculated as the B/C ratio. In the present
subpopulation, the C-PP measured by tonometry and pulse
wave analysis was compared with the values calculated from
a sex-specific multiple regression analysis deduced from the
same 834 patients studied, including 480 men and 354
women (equations are shown in the expanded Methods
section; please see the Online Appendix). To further vali-
date the C-PP evaluation, we applied these equations to
another distinct population of 285 individuals (147 men,
138 women), investigated in the Nancy Hospital (France)
(24,25) (please see the expanded Methods in the Online Appen-
dix). We calculated the correlation between the evaluated
Characteristics of the Population According to Sex and AgeTable 1 Characteristics of the Population According to Sex an
Men
Age <55 yrs
(n  62,888)
Age >55 yrs
(n  9,549)
Age (yrs) 38.3 9.1 58.9 4.7
Weight (kg) 73.7 10.6 75.4 10.8
Height (cm) 174.2 6.7 171.2 6.6
Body mass index (kg/m2) 24.3 3.2 25.7 3.2
Plasma glycemia (g/l) 1.02 0.12 1.07 0.20
Plasma creatinine (mg/l) 10.41 1.25 10.66 1.48
Plasma cholesterol (g/l) 2.17 0.45 2.37 0.42
Systolic blood pressure (mm Hg) 133.8 12.8 142.5 16.3
Diastolic blood pressure (mm Hg) 82.2 9.8 87.8 10.6
Mean arterial pressure (mm Hg) 99.4 10.2 106.0 11.9
Heart rate 80 beats/min 10,142 (16.1) 1626 (17.0)
Brachial PP (mm Hg) 51.6 8.3 54.7 10.1
Carotid PP (mm Hg) 33.5 7.0 38.8 8.8
Brachial/carotid PP 1.56 0.10 1.43 0.09
Hypertensive subjects 26,530 (42.2) 6,495 (68.1)
Antihypertensive treatment* 1,459 (2.32) 967 (10.1)
Current smokers 22,238 (35.4) 2,269 (23.8)
Subjects with aspirin treatment or
anti-inflammatory agent
4,879 (7.8) 990 (10.4)
All-cause mortality 1,929 (3.1) 1,099 (11.5)
Cardiovascular mortality 313 (0.5) 287 (3.0)
Values are mean  SD or n (%). *With or without antidiabetic or hypolipidemic agent.
PP  pulse pressure.-PP and the measured C-PP using the same methodology a(applanation tonometry) but performed by another trained
investigator. The observed R2 values were 0.888 (p 
0.0001) in men and 0.889 (p  0.0001) in women. The
land-Altman analysis for comparison of both methods for
entral PP determination showed that the 2 SDs for
ndividual differences was 12.18 mm Hg in men and 12.45
m Hg in women, without any drift of the regression lines
please see the expanded Methods section in the Online
ppendix). The mean value for the individual difference in
-PP was 0.50 mm Hg in men and 6.45 mm Hg in
omen. After this validation, the calculation of C-PP was
hen applied to the total IPC population.
tatistical analysis. The impact of B-PP and C-PP and
P amplification (B/C ratio) on all-cause and CV mortality
as evaluated using Cox regression models, including age,
ex, height, weight, and risk factors (smoking, physical
ctivity, cholesterol, and diabetes mellitus). Additional ad-
ustment for MAP in the Cox regression model was also
erformed. Because the B/C ratio is known to be highly
nfluenced by pulse rate (13), models also included pulse rate
s an adjusting factor. Hazard ratios (HR) for all-cause and
V mortalities (HR and 95% confidence interval [CI]) were
alculated for each increase of 1 SD of B-PP, C-PP, and the
/C ratio. All quantitative variables used in the regression
odel or in the C-PP equation were normally distributed,
nd colinearity assessment was taken into account in mul-
ivariate analysis. The presence or absence of antihyperten-
ive therapy did not modify the results. For overall mortality,
Women
Age
Effect
Gender
Effect
Age–Gender
Interaction
55 yrs
46,187)
Age >55 yrs
(n  6,527)
 9.5 58.9 4.9
 9.4 61.2 10.2 0.0001 0.0001 0.0001
 6.2 158.0 6.0 0.0001 0.0001 0.0001
 3.5 24.5 3.9 0.0001 0.0001 0.0001
 0.10 1.03 0.14 0.0001 0.0001 0.0001
 1.15 8.76 1.35 0.0001 0.0001 0.0008
 0.39 2.49 0.42 0.0001 0.0001 0.0001
 12.9 139.9 17.2 0.0001 0.0001 0.0001
 9.6 85.3 10.4 0.0001 0.0001 0.0001
 10.1 85.3 10.4 0.0001 0.0001 0.0001
9 (20.1) 1173 (18.0) 0.0001 0.0001 0.0001
 8.1 54.7 10.9 0.0001 0.0001 0.0001
 7.1 47.2 9.4 0.0001 0.0001 0.0001
 0.04 1.16 0.01 0.0001 0.0001 0.0001
1 (22.3) 3,883 (59.7) 0.0001 0.0001 0.0001
4 (2.46) 939 (14.4) 0.0001 0.0001 0.0001
0 (25.3) 702 (10.8) 0.0001 0.0001 0.0001
8 (14.0) 1,318 (20.2) 0.0001 0.0001 0.0001
4 (1.3) 365 (5.6) 0.0001 0.0001 0.0001
7 (0.12) 78 (1.2) 0.0001 0.0001 0.0001d Age
Age <
(n 
36.8
58.1
161.1
22.4
0.95
8.46
2.00
126.6
77.3
93.8
9,26
49.3
39.9
1.24
10,30
113
11,67
6,46
60
5single model for C-PP showed, in the total population, a sex
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Sex Difference and PP Amplification May 15, 2012:1771–7interaction for the B/C ratio (p  0.0001; data not shown)
hat allowed us to perform a separate analysis in men and
omen. To evaluate the effect of sex, Cox regression models
ere carried out separately in men and women. To compare
he effect of sex in both age classes, a Cox regression model,
ncluding an interaction term between sex and B/C ratio,
as calculated.
Secondly, the effect of age was investigated by dividing
en and women into 2 categories (55 or55 years of age)
nd analyzing men and women separately. The threshold of
5 years of age was chosen for this analysis because of its
ink with the menopause. HRs were adjusted for height,
eight, risk factors (smoking, physical activity, cholesterol,
nd diabetes mellitus), and heart rate. The interaction of age
as calculated.
All statistical analyses, including interactions, were per-
ormed with SAS statistical software (version 8.2, SAS
nstitute, Cary, North Carolina), and a p value 0.05 was
onsidered significant.
esults
linical characteristics of the population. The popula-
ion was composed of 72,437 men (age 41.0  11.1 years)
nd 52,714 women (age 39.5  11.6 years). MAP was
00.3  10.7 mm Hg in men and 95.0  10.8 mm Hg in
women. B-PP was 52.0  8.6 mm Hg and 49.9  8.7 mm
Hg, calculated C-PP was 34.2  7.5 mm Hg and 40.8 
7.8 mm Hg, and the B/C ratio was 1.54  0.11 and 1.23 
0.05 in men and women, respectively (p  0.0001).
Table 1 shows the characteristics of the population
divided into 2 categories of age. The younger men had
the highest mean value of B/C ratio (1.56  0.10), whereas
the older women showed the lowest (1.16  0.01). The
sex–age interaction was significant, with a greater decrease
in B/C ratio with age in men than in women. A sex–age
interaction was also observed for B-PP and C-PP sepa-
rately. The mortality risk increased with age, particularly the
CV risk of death: 0.5% in men 55 years of age, and 3.0%
in men 55 years of age, and 0.12% and 1.2% in women,
respectively. The age–sex interaction was significant with a
greater increase in CV mortality with age in women than in
men.
Risk of mortality according to sex. For all-cause mortality
and CV mortality (Table 2), the HRs for B-PP, calculated
C-PP, and B/C ratio were highly significant in the overall
population.
Concerning all-cause mortality, the B/C ratio HR was
significantly different between men and women after adjust-
ment for age, height, weight, smoking, physical activity,
cholesterol, diabetes mellitus, and heart rate; the HR was
higher in women than in men (p  0.0001). However, the
differences observed for B-PP and C-PP HRs between sexes
were not statistically significant. The CV mortality risk
associated with the B/C ratio was also higher in women
than in men (p  0.0001) and moreover, similar significantsex differences in HR were observed for both B-PP and
C-PP.
Sex interaction of risk according to age. The p values of
sex interactions in the total population showed, for overall
mortality, a sex interaction observed for the B/C ratio in
patients both 55 and 55 years of age (p  0.0001). For
CVD mortality, p values were significant for C-PP (p 
0.04) in those 55 years of age and for the B/C ratio in
those 55 and 55 years of age (p  0.008 and p 
0.0001, respectively).
Figure 1 shows values of HRs for CV risk associated with
the B/C ratio and sex interactions in men and women in the
2 age groups (55 and 55 years of age). This HR was
higher for women than for men. In men, the change in HR
with age was not statistically significant (HR: 1.44 [95% CI:
1.31 to 1.58] vs. HR: 1.65 [95% CI: 1.48 to 1.84]), but for
women it significantly increased (HR: 3.19 [95% CI: 2.08 to
4.89] vs. HR: 5.60 [95% CI: 4.17 to 7.50]) (p  0.01). The
mortality impact of the B/C ratio was 3-fold higher in
women than in men 55 years of age (p  0.0001). The
inclusion of MAP as a covariate (data not shown) or a
supplementary adjustment on MAP did not alter these
results (men 55 years: HR: 1.29 [95% CI: 1.17 to 1.42];
men 55 years: HR: 1.56 [95% CI: 1.39 to 1.74]; women,
55 years: HR: 2.59 [95% CI: 1.67 to 4.02]; women 55
years: HR: 5.83 [95% CI: 4.29 to 7.92]).
Discussion
In this study, we investigated a large sample of the general
population in whom we measured B-PP noninvasively and
also calculated C-PP. The validation of the methodological
basis of the C-PP calculation was already published (13).
C-PP was measured using a tonometric sensor in a first
unrelated population of 834 patients to evaluate the deter-
minants of C-PP, among the classical parameters available
in a large cohort of subjects. We further confirmed this
validation in a second unrelated population.
Both C-PP and B-PP individually had significant pre-
Adjusted Risk (HR) ofll-Cause Mortality and CV Mortalityccording t Sex in the Overall Population
Table 2
Adjusted Risk (HR) of
All-Cause Mortality and CV Mortality
According to Sex in the Overall Population
Men Women p Value
All-cause mortality HR
Brachial PP 1.17 (1.14–1.21) 1.07 (1.01-1.14) 0.31
Carotid PP 1.39 (1.35–1.44) 1.35 (1.28-1.42) 0.88
B/C ratio 1.51 (1.47–1.56) 2.46 (2.27–2.67) 0.0001
CV mortality HR
Brachial PP 1.18 (1.11–1.25) 1.25 (1.12–1.40) 0.02
Carotid PP 1.50 (1.42–1.59) 1.72 (1.57–1.89) 0.01
B/C ratio 1.81 (1.70–1.93) 4.46 (3.66–5.45) 0.0001
Adjusted risk of all-cause mortality and cardiovascular (CV) mortality (hazard ratio [HR] and 95%
confidence interval) associated with the increase of 1 SD in brachial pulse pressure (PP), carotid
PP, and carotid/brachial (B/C) ratio. Adjustments were made for age, height, weight, smoking,
physical activity, cholesterol, diabetes mellitus, and heart rate. Additional adjustment for gender
was performed for the overall group analysis. *Men versus women.dictive value on overall and CV mortality, independently of
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May 15, 2012:1771–7 Sex Difference and PP Amplificationstandard CV risk factors. Furthermore, PP amplification,
expressed as the B/C ratio, was strongly associated with
both CV and overall mortality risk, with a much higher HR
for the B/C ratio compared with that of B-PP or C-PP
alone. Thus, after adjustment for age, height, standard risk
factors, drug treatment, and heart rate, a decrease in PP
amplification of 1 SD was associated with an increase of
51% for all-cause mortality, an 81% increase for CV
mortality in men, a 146% increase for women for overall
mortality, and a 346% increase for CV mortality. In our
population, heart rate was not included in the equation for
calculation of C-PP because in the database it was classified
according to categories with arbitrary cut-off points (i.e.,
60, 60 to 80, 80 to 100, and 100 beats/min), and, as
such, it accounted for only 2% of variability of C-PP.
However, the results were adjusted for heart rate. The
CAFE (Conduit Artery Function Evaluation) study showed
that heart rate explained 9% of central pulse pressure
measured with Sphygmocor (AtCor, Sydney, Australia)
Figure 1 Forest Plot
Adjusted risk of all-cause (A) and cardiovascular mortality (B) according to sex
and age (open diamonds  men; solid diamonds  women). Hazard ratio (95%
confidence interval) associated with the increase of 1 SD in brachial pulse
pressure (PP), carotid PP, and/or the decrease of 1 SD in brachial/carotid
(B/C) PP ratio. Adjustments were made for height, weight, risk factors (smok-
ing, physical activity, cholesterol, and diabetes mellitus), and heart rate.(26). The facts that the population studied was a hyperten- dsive population with high risk and that the beginning of the
arterial study took place after the first year of the inclusion
and treatment probably explains this unexpectedly high
impact. Finally, the disappearance of PP amplification
indicated a significantly higher risk of CV mortality in
women than in men. Because only a relatively small number
of subjects, particularly women, died during the observation
period, this finding was probably slightly underestimated.
An important advantage of the present C-PP calculation
results from the use of a validated stepwise multiple regres-
sion, which associates hemodynamic and biological variables
with a very high proportion of explained variance (86%)
(13). When PP amplification is calculated as the B/C ratio,
this ratio is influenced only by the reliability of detection of
the B-PP by the auscultatory method and the methodology
used to estimate the central aortic or carotid pulse (9,20,21).
The present study confirms that all-cause mortality and
CV mortality (Table 1) are higher in men than in women,
both at 55 and 55 years of age. However, there is a
reater increase in CV mortality with age in women than in
en, and the major finding of this study concerns the
mpact of the B/C ratio on CV mortality. This impact is
argely increased in women 55 years compared with
ounger women. Such an increase was not observed in men.
t 55 years of age, the impact of the B/C ratio on CV
ortality was 3-fold higher in women than in men. The
ain putative cause of this sex difference is the menopausal
hange, particularly via its effects on large artery behavior
1–7) and CV events. The fact that the most important
bservations of this study concerned the large arteries of
lder women (55 years), suggests that, independently of
he standard aging process, the loss of estrogenic action in
he carotid and brachial arterial wall might play a specific
eleterious role, increasing arterial stiffness and reducing
lasticity, as previously observed by others (27–29). We
how, for the first time, that in men, the well-established
ncrease in aortic stiffness with age (30,31) does not result
n the same epidemiological consequences as in women.
e propose that the B/C ratio should be interpreted,
aking into account estrogenic status as recently demon-
trated by our group in the metabolic syndrome, which is
ainly associated with hormonal changes and inflamma-
ion (32).
tudy limitations. Some limitations of the study should be
cknowledged. As mentioned, we were not able to directly
easure the carotid artery PP by applanation tonometry in
hese 125,151 subjects. However, we tried hard to circum-
ent this limitation by a calculation based on a subgroup of
34 subjects of both sexes and to validate the sex equations
n 285 individuals studied in the Nancy Hospital (V.R.,
.L.). We did not include heart rate in the calculation of
-PP because it was classified into categories with arbitrary
utoff points and accounted for no2% in the variability. A
econd limitation is the lack of data on morbidity for these
25,151 subjects, particularly in the CV domain. Our
atabase does not include such data. However, the mortality
L1776 Regnault et al. JACC Vol. 59, No. 20, 2012
Sex Difference and PP Amplification May 15, 2012:1771–7data are robust and have been previously validated. The
cause of death is drawn from the only official French
institution that documents French mortality, the Cepid
INSERM (SC8 department of the National French Insti-
tute of Health and Medical Research). It is clear that in the
field of CV disease, particularly in the 1980s, the CV
mortality rate did not correspond to the general impact of
the disease because of the many successful interventional
coronary and arterial procedures. However, we are con-
vinced of the robustness of the data, despite this limitation,
particularly in view of the large size of the sample studied.
The menopause status was not specifically assessed in our
questionnaire. However, we have obtained data in a differ-
ent subpopulation of the IPC cohort, suggesting that at 55
years of age 98% of women have gone through menopause.
The last limitation is the lack of high-density lipoprotein
and low-density cholesterol data for assessing risk factors
and CV mortality. Unfortunately, our database at the period
of this cohort did not include the measurement of high-
density lipoprotein cholesterol. We thus adjusted for total
cholesterol in our analysis.
Conclusions
This epidemiological study shows that a large scale evalua-
tion of central to peripheral pulsatility amplification is
independently associated with CV mortality. However, it is
not applicable to the individual calculation of carotid artery
PP for clinical use. In the past, studies of BP in menopausal
and post-menopausal women have largely been based on its
steady component, MAP, and consequently on its principal
determinant, total peripheral resistance (small arteries) (33).
Using the B/C ratio, our findings show that 3 major
components of arterial pressure are involved in hemody-
namics and prognosis: steady pressure, PP, and regional
distribution of pulsatility. We show for the first time that
the latter component is a major contributor to mortality risk,
principally in women (30,34). For this reason, the effects of
menopausal hormonal therapy in controlled trials should be
analyzed in older women on the following basis: 1) the
choice of drugs acting on arterial stiffness and wave reflec-
tions, which depends on the status of pre-existing CV
disease; 2) the specific analysis of the type of estrogen used,
and its dose and mode of administration (probably acting
differently on small and large arteries); and 3) epidemiolog-
ical findings principally evaluated in women. We speculate
on such a basis, that the optimal antihypertensive drug
therapy of hypertension should differ markedly between
men and women.
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APPENDIX
For the expanded Methods section,
please see the online version of this article.
